Form 4: Theravance Biopharma CEO's Tax-Related Stock Disposition

Theravance Biopharma CEO Rick E Winningham disposed of 74,975 ordinary shares to cover tax obligations arising from vested restricted stock units.

Summary

• Rick E Winningham, Chief Executive Officer and Director of Theravance Biopharma, Inc. (TBPH), reported a disposition of ordinary shares.
• The transaction involved 74,975 ordinary shares disposed of at a price of $19.66 per share.
• This disposition was a non-open market transaction with the issuer, specifically for satisfying tax obligations related to the vesting of previously granted restricted stock units.
• Following the transaction, Mr. Winningham directly beneficially owns 1,576,094 ordinary shares.
• Additionally, Mr. Winningham indirectly beneficially owns 23,400 ordinary shares as Custodian and 92,567 ordinary shares by Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine, non-discretionary transaction for tax purposes related to equity compensation and does not indicate a change in company fundamentals or management's confidence.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that this Form 4 filing details a routine insider transaction, specifically a tax-related disposition of shares. Such transactions are common for executives who receive equity compensation, like restricted stock units, as shares are often withheld by the company to cover income tax liabilities upon vesting. This is a standard administrative event and typically does not reflect a discretionary sale or a change in management's outlook on the company.

Related Party Transactions

• The share withholding transaction was conducted directly with the issuer (Theravance Biopharma, Inc.) to satisfy tax obligations, rather than through an open market sale. This is a common form of related-party dealing for equity compensation.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary tax-related transaction by an executive, not indicative of a change in investment thesis.
• Employees: No direct impact on the broader employee base.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary disposition of shares by the CEO to cover tax obligations from vested restricted stock units. Such transactions are standard for executives receiving equity compensation and do not provide new information that would warrant a change in investment recommendation. The core investment thesis for Theravance Biopharma remains unchanged based on this filing.

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Transaction, Stock Disposition, CEO, Rick E Winningham, Restricted Stock Units, Tax Withholding